Sumatriptan is a selective serotonin (5-HT₁B/1D) receptor agonist used for the acute treatment of migraine attacks and cluster headaches. It works by inducing vasoconstriction in cranial blood vessels and inhibiting the release of inflammatory neuropeptides involved in migraine pathophysiology.
Sumatriptan is available in multiple dosage forms including:
∙ Oral tablets
∙ Subcutaneous injections
∙ Nasal sprays
∙ Transdermal patches (in some regions)
It provides rapid migraine relief, especially when administered by injection.
Indications include:
∙ Acute treatment of migraine with or without aura
∙ Cluster headache episodes
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan
Parent: Sumatriptan Succinate
Impurities in sumatriptan may form during chemical synthesis or as degradation products under environmental stress. Regulatory agencies such as the USP, EP, and ICH require that these impurities be identified, monitored, and controlled within specified limits.
Process-Related Impurities
Degradation Impurities
Elemental Impurities
Analytical Techniques for Impurity Detection
Sumatriptan is used to relieve the symptoms of acute migraine attacks and cluster headaches. It is not used for migraine prevention or long-term prophylaxis.
It activates 5-HT₁B/1D receptors in cranial blood vessels, leading to vasoconstriction and inhibition of pain-signaling neuropeptides.
Caution is advised. Sumatriptan is contraindicated in patients with a history of cardiovascular disease, uncontrolled hypertension, or ischemic heart conditions due to its vasoconstrictive properties.
Yes, it is sensitive to light and moisture. Proper storage in a tightly sealed container away from light and humidity is essential to prevent degradation.
